TY - JOUR
T1 - IL-1β-induced apoptosis in rat gastric enterochromaffin-like cells is mediated by iNOS, NF-κB, and bax protein
AU - Mahr, Sabine
AU - Neumayer, Nina
AU - Gerhard, Markus
AU - Classen, Meinhard
AU - Prinz, Christian
N1 - Funding Information:
Supported by grants from the Deutsche Forschungsgemeinschaft (DFG 411/2-2) (to C.P.) and from the Technical University of Munich (KKF 8733151 and 8733156) (to C.P.). Dr. Prinz is a recipient of the Heisenberg Award of the Deutsche Forschungsgemeinschaft (DFG Pr 411/7-1)
PY - 2000
Y1 - 2000
N2 - Background and Aims: Enterochromaffin-like (ECL) cells are histamine- containing endocrine cells in the gastric mucosa. Previous studies have shown that the proinflammatory cytokine interleukin (IL)-1β present during chronic gastritis inhibits histamine synthesis in ECL cells and leads to sustained functional impairment. This study investigated the effects of IL-1β on ECL cell apoptosis and the related signal-transduction mechanisms. Methods: ECL cells were isolated by pronase digestion and a combination of elutriation, gradient centrifugation, and 48-hour culture (purity ≥90%). Apoptosis was measured by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling reaction and cell death detection enzyme- linked immunosorbent assay. Results: IL-1β (100 pg/mL) increased the rate of programmed cell death 2-3 fold in ECL cells after 24 hours of incubation (total of 12%-14%). This effect was completely inhibited by the NF-κB inhibitor, proteasome inhibitor I, and the nitric oxide synthase inhibitor (iNOS) N(G)-monomethyl-L-arginine (10-4 mol/L), but not by the caspase 3 inhibitor, Asp-Glu-Val-Asp-CHO. Western blot analysis, reverse-transcription polymerase chain reaction (PCR), and in situ PCR showed that IL-1β induced gene expression (after 2-4 hours) and protein synthesis (6-18 hours) of the iNOS isoform in ECL cells. Bax protein expression was increased in response to IL-1β. In contrast, bcl-2 gene expression was increased in response to basic fibroblast growth factor, which has been shown to counteract IL-1β- induced apoptosis. Conclusions: These data suggest that IL-1β induces programmed cell death in isolated rat ECL cells via activation of NF-κB, iNOS, and the Bax protein.
AB - Background and Aims: Enterochromaffin-like (ECL) cells are histamine- containing endocrine cells in the gastric mucosa. Previous studies have shown that the proinflammatory cytokine interleukin (IL)-1β present during chronic gastritis inhibits histamine synthesis in ECL cells and leads to sustained functional impairment. This study investigated the effects of IL-1β on ECL cell apoptosis and the related signal-transduction mechanisms. Methods: ECL cells were isolated by pronase digestion and a combination of elutriation, gradient centrifugation, and 48-hour culture (purity ≥90%). Apoptosis was measured by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling reaction and cell death detection enzyme- linked immunosorbent assay. Results: IL-1β (100 pg/mL) increased the rate of programmed cell death 2-3 fold in ECL cells after 24 hours of incubation (total of 12%-14%). This effect was completely inhibited by the NF-κB inhibitor, proteasome inhibitor I, and the nitric oxide synthase inhibitor (iNOS) N(G)-monomethyl-L-arginine (10-4 mol/L), but not by the caspase 3 inhibitor, Asp-Glu-Val-Asp-CHO. Western blot analysis, reverse-transcription polymerase chain reaction (PCR), and in situ PCR showed that IL-1β induced gene expression (after 2-4 hours) and protein synthesis (6-18 hours) of the iNOS isoform in ECL cells. Bax protein expression was increased in response to IL-1β. In contrast, bcl-2 gene expression was increased in response to basic fibroblast growth factor, which has been shown to counteract IL-1β- induced apoptosis. Conclusions: These data suggest that IL-1β induces programmed cell death in isolated rat ECL cells via activation of NF-κB, iNOS, and the Bax protein.
UR - https://www.scopus.com/pages/publications/0033621826
U2 - 10.1016/S0016-5085(00)70257-5
DO - 10.1016/S0016-5085(00)70257-5
M3 - Article
C2 - 10702202
AN - SCOPUS:0033621826
SN - 0016-5085
VL - 118
SP - 515
EP - 524
JO - Gastroenterology
JF - Gastroenterology
IS - 3
ER -